Beeline Medicines Corporation

Based in the US, Beeline Medicines Corporation focuses on advancing precision therapies for autoimmune and inflammatory diseases, specifically targeting conditions like lupus through innovative drug development. Beeline Medicines Corporation develops precision therapies targeting autoimmune and inflammatory diseases, with its headquarters in Boston, US. Founded in 2025, the company raised USD 300 mn in Series A funding on July 28, 2025, led by Bain Capital. The founder's previous ventures are not disclosed, and there are no recorded pivots or subsidiaries.

Beeline Medicines specializes in developing precision therapies for autoimmune and inflammatory diseases. Its flagship product, afimetoran, is a selective oral small molecule inhibitor that targets TLR7 and TLR8, crucial in lupus pathogenesis. Additional products include BMS-986326, an IL-2-CD25 fusion protein aimed at enhancing regulatory T cell function, and lomedeucitinib, a next-generation TYK2 inhibitor for various autoimmune conditions, primarily serving patients in the US and Europe. Beeline Medicines operates a clinical-stage model, generating revenue mainly through licensing agreements and partnerships that facilitate the commercialization of their therapies.

This includes upfront payments at partnership initiation, milestone payments linked to regulatory approvals, and royalties from product sales. The specific pricing for their products has not been disclosed, but their offerings focus on providing clinical value to enhance patient outcomes. With the recent Series A funding of USD 300 mn, Beeline Medicines plans to advance the development of five immunology drug candidates licensed from Bristol Myers Squibb. This includes transitioning its lead lupus program, afimetoran, from Phase 2 to Phase 3 trials.

The company is focused on further expanding its market presence in both the US and Europe, with strategic initiatives aimed at increasing access to their therapies for patients suffering from autoimmune diseases.